In this study, we are investigating whether personalized, risk-adapted therapy improves treatment outcomes and reduces toxicity in post-pubertal patients with medulloblastoma. We also hypothesize that clinical data, magnetic resonance imaging (MRI) data and voxel-based radiotherapy planning, as well as biomarkers from liquid biopsies and tumor tissue samples, can be processed to improve diagnosis and treatment and reduce toxicity.